CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI ® is ...

Lakshmi Narasimha Rohit Madhukar Emani's work demonstrates how aerospace thinking, grounded in validation, optimization, and ...

Many enterprise AI initiatives continue to struggle — with 95% failing to deliver ROI due to inadequate data infrastructure ...